Nutex Health, Inc. (NUTX) vs Stoke Therapeutics, Inc. (STOK)

A side-by-side comparison of Nutex Health, Inc. and Stoke Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — NUTX vs STOK

growth of $100 · dividends reinvested · last 7y
NUTX -24.6% (-4.0%/yr)STOK -1.0% (-0.1%/yr)STOK compounded faster over this window
0200400600800Start $100202120232025$75$99
NUTX STOK

NUTX vs STOK: by the numbers

  • •STOK is the larger company ($1.56B vs $1.52B market cap).
  • •NUTX is profitable (21.25% net margin) while STOK runs a net loss (-753.60%).

Metrics side by side

Valuation

MetricNUTXSTOK
P/E ratio8.74N/A
Forward P/E7.95N/A
P/S ratio1.8056.57
P/B ratio3.864.52
EV / EBITDA4.32N/A
FCF yield18.03%N/A

Profitability

MetricNUTXSTOK
Gross margin51.26%100.00%
Operating margin31.49%-11.16%
Net margin21.25%-753.60%
ROE45.63%-60.17%
ROIC33.76%-63.12%

Growth (annualized)

MetricNUTXSTOK
Revenue CAGR (5Y)37.66%N/A
EPS CAGR (5Y)-14.73%N/A
Total return CAGR (5Y)-18.99%-0.24%

Frequently asked

Is NUTX or STOK more profitable?
NUTX runs the higher net margin — NUTX at 21.25% versus STOK at -753.60%.
How have NUTX and STOK total returns compared?
Over the past 5 years, NUTX delivered -18.99% and STOK delivered -0.24% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.